Key result
High preoperative peak troponin (>1.95 ng/dl) was not associated with increased hazards for MACCE, mortality, or readmission following CABG for NSTEMI compared to levels ≤1.95 ng/dl.
Why the study?
This study evaluated the impact of peak preoperative troponin level on outcomes of CABG for NSTEMI.
Does peak preoperative troponin level predict MACCE and mortality in patients undergoing CABG for NSTEMI?
Cohort (n=1,211)
Does peak preoperative troponin level predict MACCE and mortality in patients undergoing CABG for NSTEMI?
Preoperative troponin levels do not predict short- or long-term outcomes following CABG for NSTEMI and should not dictate clinical decisions regarding surgical revascularization.
Preop troponin >1.95 ng/dl may not increase post-CABG risk in NSTEMI; leaves open its role in risk models pending prospective validation.
BACKGROUND: This study evaluates the impact of peak preoperative troponin level on outcomes of coronary artery bypass grafting (CABG) for non-ST-elevation myocardial infarction (NSTEMI). METHODS: This was a retrospective review of patients undergoing isolated CABG from 2011 to 2018 with the presentation of NSTEMI. Patients were stratified into low- and high-risk groups based on median preoperative peak troponin (1.95 ng/dl). Major adverse cardiac and cerebrovascular events (MACCE) and mortality were compared. Multivariable analysis was performed to model risk factors for MACCE and mortality. RESULTS: This study included 1211 patients, 607 low-risk (≤1.95 ng/dl) and 604 high-risk (>1.95 ng/dl). Patients were well-matched with respect to age and comorbidity. High-risk patients had lower median preoperative ejection fraction (46.5% [interquartile range {IQR}: 35.0%-55.0%] vs. 53.0% [IQR: 40.0%-58.0%]) and higher incidence of preoperative intra-aortic balloon pump (15.9% vs. 8.73%). Intensive care unit and hospital length of stay were longer in the high-risk group, but increasing troponin level was not associated with prolonged intensive care or hospital length of stay (>4 and >14 days, respectively) after risk adjustment. Postoperative complications and 30-day, 1- and 5-year rates of both MACCE and survival were similar between groups. Peak troponin greater than 1.95 ng/dl was not associated with increased hazards for MACCE, mortality, or readmission in multivariable modeling. In subanalysis, neither increasing troponin as a continuous variable nor peak troponin greater than 10.00 ng/ml were associated with increased hazards for these outcomes. CONCLUSIONS: Preoperative troponin levels do not appear to be predictive of short- or long-term outcomes following CABG, and clinical decisions regarding surgical revascularization should not be dictated by these measurements.
No takes yet. Share an insight, caveat, or question.
Hess et al. (2021) conducted a cohort in Non-ST-elevation myocardial infarction (NSTEMI) requiring CABG (n=1,211). High preoperative peak troponin (>1.95 ng/dl) vs. Low preoperative peak troponin (≤1.95 ng/dl) was evaluated on Major adverse cardiac and cerebrovascular events (MACCE) and mortality. High preoperative peak troponin (>1.95 ng/dl) was not associated with increased hazards for MACCE, mortality, or readmission following CABG for NSTEMI compared to levels ≤1.95 ng/dl.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: